Teva Pharmaceutical Industries Ltd. has executed an amendment to its Second Amended and Restated Deposit Agreement, dated December 4, 2018, among the Company, Citibank, N.A., as depositary, and holders of American depositary shares (ADSs). The amendment, dated August 31, 2026, also updates the form of the American depositary receipt (ADR) evidencing the ADSs.
Each ADS represents one ordinary share of the Company, which has a par value of NIS 0.10 per share. The amendment establishes a mechanism for the mandatory exchange of ADSs for ordinary shares. This process is intended to facilitate the termination of the ADS program.
The Company previously disclosed its intent to list its ordinary shares on the New York Stock Exchange (NYSE) and instructed the depositary to terminate the ADS program. The termination is scheduled to occur at the open of business in New York on September 14, 2026. At that time, all outstanding ADSs will be cancelled in exchange for an equal number of NYSE-listed ordinary shares.
Exhibits 4.1 and 4.2 attached to the filing contain the full text of the Amendment No. 1 and the updated ADR form, respectively.
